
|Videos|June 9, 2022
Dr. Roger Li on CG0070 combined with pembrolizumab in NMIBC unresponsive to BCG
Author(s)Urology Times staff
“I think immunotherapy in the neoadjuvant and also in the BCG-unresponsive setting are here to stay,” says Roger Li, MD.
Advertisement
In this video, Roger Li, MD, discusses the 2022 ASCO Annual Meeting study, “CORE1: Phase 2, single-arm study of CG0070 combined with pembrolizumab in patients with nonmuscle-invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette-Guerin (BCG).” Li is a genitourinary oncologist at Moffitt Cancer Center in Tampa, Florida.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Team-based AE protocols improve consistency with the gemcitabine intravesical therapy system
2
Practical tips for AE management with the gemcitabine intravesical system
3
Jamie Michael, MD, discusses MRI and genomics in active surveillance
4
Department of Defense announces annual testosterone deficiency screening for service members
5











